87 related articles for article (PubMed ID: 1106918)
21. Blocking of the hemolytic expression of the classical complement sequence by products of complement activation via the alternate pathway. Materials responsible for the blocking phenomenon and their proposed mechanism of action.
Koethe SM; Austen KF; Gigli I
J Immunol; 1973 Feb; 110(2):390-400. PubMed ID: 4684033
[No Abstract] [Full Text] [Related]
22. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan.
Schenkein HA; Ruddy S
J Immunol; 1981 Jan; 126(1):7-10. PubMed ID: 6778918
[TBL] [Abstract][Full Text] [Related]
23. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
24. Is Apolipoprotein A-I a regulating protein for the complement system of cod (Gadus morhua L.)?
Magnadóttir B; Lange S
Fish Shellfish Immunol; 2004 Feb; 16(2):265-9. PubMed ID: 15123329
[No Abstract] [Full Text] [Related]
25. Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor.
Czop JK; Austen KF
J Immunol; 1985 Nov; 135(5):3388-93. PubMed ID: 4045195
[TBL] [Abstract][Full Text] [Related]
26. Effect of age-dependent enzymatic degradation of zymosan into oligosaccharides during incubation with serum on its opsonization by complement.
Everaerts MC; Van den Berghe G; Saint-Remy JM; Corbeel L
Pediatr Res; 1985 Dec; 19(12):1293-7. PubMed ID: 2417186
[TBL] [Abstract][Full Text] [Related]
27. Activation, activities and pharmacologically active products of complement.
Vogt W
Pharmacol Rev; 1974 Jun; 26(2):125-69. PubMed ID: 4609350
[No Abstract] [Full Text] [Related]
28. Binding characteristics of three complement dependent assays for the detection of immune complexes in human serum.
Krieger G; Kneba M; Bolz I; Volling P; Wessels J; Nagel GA
J Clin Lab Immunol; 1985 Nov; 18(3):129-34. PubMed ID: 3878887
[TBL] [Abstract][Full Text] [Related]
29. Bypass-activation of the complement system starting with C3. I. Generation and function of an enzyme from a factor of guinea-pig serum and cobra venom.
Bitter-Suermann D; Dierich M; König W; Hadding U
Immunology; 1972 Sep; 23(3):267-81. PubMed ID: 4214761
[TBL] [Abstract][Full Text] [Related]
30. Serum amyloid P component forms a stable complex with human C5b6.
Barbashov SF; Wang C; Nicholson-Weller A
J Immunol; 1997 Apr; 158(8):3830-5. PubMed ID: 9103450
[TBL] [Abstract][Full Text] [Related]
31. C3 shunt activation in human serum chelated with EGTA.
Fine DP; Marney SR; Colley DG; Sergent JS; Des Prez RM
J Immunol; 1972 Oct; 109(4):807-9. PubMed ID: 4627510
[No Abstract] [Full Text] [Related]
32. Ability of complement to release systemic lupus erythematosus immune complexes from cell receptors.
Medof ME; Scarborough D; Miller G
Clin Exp Immunol; 1981 May; 44(2):416-25. PubMed ID: 7307341
[TBL] [Abstract][Full Text] [Related]
33. Action of chlorogenic acid on the complement system.
Ejzemberg R; Da Silva MH; Pinto L; Mors WB
An Acad Bras Cienc; 1999; 71(2):273-7. PubMed ID: 10412494
[TBL] [Abstract][Full Text] [Related]
34. Suboptimal C3b/C3bi deposition and defective yeast opsonization. II. Partial purification and preliminary characterization of an opsonic co-factor able to correct sera with the defect.
Turner MW; Seymour ND; Kazatchkine MD; Mowbray JF
Clin Exp Immunol; 1985 Nov; 62(2):435-41. PubMed ID: 3910314
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of complement-mediated functions of human neutrophils by impermeant stilbene disulfonic acids.
Tauber AI; Goetzl EJ
J Immunol; 1981 May; 126(5):1786-9. PubMed ID: 6260856
[TBL] [Abstract][Full Text] [Related]
36. Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis.
Berman S; Gewurz H; Mold C
J Immunol; 1986 Feb; 136(4):1354-9. PubMed ID: 3944459
[TBL] [Abstract][Full Text] [Related]
37. Acute-phase C56-forming ability and concentrations of complement components in normotensive and hypertensive pregnancies.
Johansen KA; Williams JH; Stark JM
Br J Obstet Gynaecol; 1981 May; 88(5):504-12. PubMed ID: 7236554
[TBL] [Abstract][Full Text] [Related]
38. THE EFFECT OF IMMUNE SERUM AND ACTIVATOR ON THE INFECTIVITY OF TOXOPLASMA GONDII FOR CELL CULTURE.
LYCKE E; LUND E; FALSEN E
Acta Pathol Microbiol Scand; 1965; 63():206-20. PubMed ID: 14302343
[No Abstract] [Full Text] [Related]
39. An alternative mechanism for the properdin system.
NELSON RA
J Exp Med; 1958 Oct; 108(4):515-35. PubMed ID: 13575682
[TBL] [Abstract][Full Text] [Related]
40. EVIDENCE FOR IMMUNOLOGICAL SPECIFICITY OF THE PROPERDIN SYSTEM; DEMONSTRATION, ISOLATION AND PROPERTIES OF A SERUM FACTOR WHICH INTERACTS WITH ZYMOSAN AND OTHER POLYSACCHARIDES AT 0 DEGREES CENTIGRADE.
BLUM L
J Immunol; 1964 Jan; 92():61-72. PubMed ID: 14139548
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
